This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Whether the results — and Immuneering’s approach — will hold up in a pivotal trial planned for 2026 remains to be seen. Editors pick stock via Getty Images GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down As more drugmakers aim for the lucrative weight loss market, patient challenges linger.
BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory in space in 2026. Then, we will need to run pre-clinical trials of these crystals, which will be in 2026 or 2027. Image credit: Rini. com/ Shutterstock.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? It is expected to enhance gross margin and contribute positively to operating income and earnings per share after 2026. Give your business an edge with our leading industry insights.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.
Anticipated next steps involve generating preclinical candidate data packages, which will include non-human primate studies expected in early 2026. How will RFK Jr’s American dream for vaccines play out? Following these outcomes, Acumen holds exclusive rights to develop up to two development candidates.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? July 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Smouldering multiple myeloma represents an asymptomatic stage in the progression to multiple myeloma.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? July 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The focus of the investment is a manufacturing facility dedicated to producing drug substances for AstraZeneca.
KalVista will receive an upfront payment of $11m, with an additional $11m contingent upon achieving a regulatory milestone anticipated by early 2026. How will RFK Jr’s American dream for vaccines play out? In April 2025, KalVista Pharmaceuticals granted Kaken Pharmaceutical the commercialisation rights for sebetralstat in Japan.
By GlobalData Learn more about Strategic Intelligence The company then plans to expand into a Phase Ib proof-of-concept trial in patients with KCNT1-related epilepsy in early 2026. The US Food and Drug Administration (FDA) has awarded ABS-1230 both orphan drug and rare paediatric designations.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.
The PRV programme for rare paediatric diseases, signed into law in 2012, expired in late 2024 after it failed to make it into a US Congress funding package. This effectively pushed the programme into its ‘sunsetting phase’. Give your business an edge with our leading industry insights.
As well as advancing DT-101, the new capital injection will also support the progression of two gamma-aminobutyric acid type A (GABA A ) receptor modulators towards clinical trials in 2026. These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options.
Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.
A target action date of 28 April 2026 has been set under the Prescription Drug User Fee Act (PDUFA). How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma Formulate Faster.
The financial impact of this agreement on JCR’s consolidated results for the fiscal year ending 31 March 2026 has already been included in the current earnings forecast. How will RFK Jr’s American dream for vaccines play out? JUST-AAV is a proprietary platform technology that employs modified AAV vectors.
A decision by the FDA is expected in H1 2026. How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma Formulate Faster. Give your business an edge with our leading industry insights.
June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The company intends to introduce its inaugural product candidate into clinical trials by 2026. The company is progressing several programmes, intending to introduce its inaugural product candidate into clinical trials by 2026.
The candidate plans to enter Phase I human trials in early 2026. Discovered through GATC’s MAT platform, the OUD candidate is a non-opioid small molecule and has shown potential in reducing fentanyl intake during preclinical studies using murine models. Give your business an edge with our leading industry insights.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.
Find out more Office of Management and Budget Director Russell Vought told reporters that the White House is on board with the substitute amendment to the rescissions package. How will RFK Jr’s American dream for vaccines play out? Data Insights The gold standard of business intelligence.
Member states of the organisation agreed earlier this year to pay 20% more in membership fees to stopgap the US funding shortfall, though WHO’s overall budget for 2026-2027 will be lower than that for 2024-2025. How will RFK Jr’s American dream for vaccines play out? Sign up for our daily news round-up!
While the CRL will delay the potential approval of UX111 to 2026, we are working with urgency to respond and resubmit.” How will RFK Jr’s American dream for vaccines play out? We have been diligently responding to the recent CMC observations and our priority is to resolve them so that we can resubmit the BLA as soon as possible. “We
However, the PRV program for rare pediatric diseases is at risk of expiry in September 2026, and is pending renewal. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.
It is an advanced sterile fill-finish and packaging site supported by more than 200 employees. How will RFK Jr’s American dream for vaccines play out? Find out more The Ridgefield site will continue to produce a range of therapies for Sanofi while expanding its capacity to meet increasing demands from other pharmaceutical and biotech firms.
Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim’s psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening its portfolio ahead of a possible public listing in 2026. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.
By GlobalData Learn more about Strategic Intelligence Moderna said it plans to have mRESVIA available for both both younger adults and older adults in the US in time for the 2025-2026 respiratory virus season. This usually begins around November and peaks in the mid-Winter months. Give your business an edge with our leading industry insights.
Sarepta Therapeutics is set to cut 500 jobs as part of its restructuring and pipeline prioritisation plan, which is expected to result in annual cash cost savings of $120m in 2026. With its pipeline reprioritisation, the company anticipates delivering $300m in annual non-personnel cost savings from 2026.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Abigail Beaney July 21, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The FDA has told Sarepta to pull the therapy and also ordered a clinical hold on another gene therapy.
As per its IPO prospectus in January, the monotherapy trial was set to commence in Q1 2025, with the combo trial slated for the same quarter in 2026. Two pre-clinical programmes also stood to benefit from cash generated from the IPO. Give your business an edge with our leading industry insights.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content